The effect of intranasal insulin on appetite and mood in women with and without obesity: an experimental medicine study

Elizabeth Schneider1, Maartje S. Spetter1,2, Elizabeth Martin1,2, Elizabeth Sapey3, Kay Por Yip3,4, Konstantinos N. Manolopoulos5,6, Abd A. Tahani5,6, Jason M. Thomas1,7, Michelle Lee8, Manfred Hallschmid9,10,11, Pia Rotshtein1,2, Colin T. Dourish12,13 and Suzanne Higgs14,15

© The Author(s) 2022

International Journal of Obesity (2022) 46:1319–1327; https://doi.org/10.1038/s41366-022-01115-1

BACKGROUND/OBJECTIVES: Intranasal (IN) administration of insulin decreases appetite in humans, but the underlying mechanisms are unclear, and it is unknown whether IN insulin affects the food intake of women with obesity.

SUBJECTS/METHODS: In a double-blind, placebo-controlled, crossover design, participants (35 lean women and 17 women with obesity) were randomized to receive 160 IU/1.6 mL of IN insulin or placebo in a counterbalanced order in the post prandial state. The effects of IN insulin on cookie intake, appetite, mood, food reward, cognition and neural activity were assessed.

RESULTS: IN insulin in the post prandial state reduced cookie intake, appetite and food reward relative to placebo and these effects were more pronounced for women with obesity compared with lean women. IN insulin also improved mood in women with obesity. In both BMI groups, IN insulin increased neural activity in the insula when viewing food pictures. IN insulin did not affect cognitive function.

CONCLUSIONS: These results suggest that IN insulin decreases palatable food intake when satiated by reducing food reward and that women with obesity may be more sensitive to this effect than lean women. Further investigation of the therapeutic potential of IN insulin for weight management in women with obesity is warranted.

Insulin is well known to act in the periphery to control blood glucose levels and promote nutrient storage. However, because the amount of insulin released is in direct proportion to the amount of body fat, and because it is able to cross the blood-brain barrier to enter the brain, insulin also acts as a central nervous system signal about levels of body fat, and simulation of brain barrier to enter the brain, insulin also acts as a central nervous

IN insulin modulates neural activity in brain regions associated with higher order cognitive processes including the hippocampus and prefrontal cortex [17–19] and improves cognitive performance, particularly hippocampal-related memory [4, 9, 10]. Memory has been shown to influence appetite [20], for example, enhancing memory of recently eaten food reduces later intake [21]. Therefore, IN insulin may reduce food intake by enhancing memory. However, there has been no comprehensive assessment of the effects of IN insulin on food intake, homeostatic, reward, cognitive and neural processes.

Another important gap in understanding the actions of IN insulin on food intake is how they vary as a function of body fat mass and insulin resistance. Individuals with obesity may be less sensitive to IN insulin and have cerebral insulin resistance. For example, in contrast to men with obesity, lean individuals report a
reduction in wanting of sweet foods after IN insulin [22]. Furthermore, effects of IN insulin on fMRI signals elicited by food stimuli are weaker or absent in individuals with type 2 diabetes or obesity [13, 15, 18, 22]. The effects of IN insulin on food intake in women with obesity have not yet been examined. This is the first multimodal study to investigate the acute effects of IN insulin on palatable food intake and hunger in satiated women with and without obesity. To assess underlying mechanisms, we included behavioural measures of homeostatic, reward, and cognitive processes and used fMRI to assess effects of IN insulin on neural activity. We also examined the effects of IN insulin on emotional responses, as mood can impact weight management interventions. We predicted that IN insulin would reduce food intake, pleasantness of food and neural activity in brain reward areas. In addition, we explored whether IN insulin enhances cognitive performance, and predicted that any effects may be less pronounced in women with obesity.

RESEARCH DESIGN AND METHODS

Participants
Fifty-four participants were recruited, but one lean and one participant with obesity withdrew during the first test day due to discomfort with having blood taken and experiencing a migraine respectively. The resulting sample consisted of thirty-five lean women and seventeen women with obesity. Assuming a small to medium effect size with 80% power, we aimed to recruit 35 participants in each BMI group but difficulties in recruitment resulted in a smaller sample size for women with obesity. Therefore, effect sizes are presented with all statistical outcomes. Participants were invited to the University of Birmingham Welcome Trust Clinical Research Facility to take part if they met the eligibility criteria and passed a screening session. Participants were recruited via posters and social media platforms and were compensated with £100. Participants provided written informed consent and the research was conducted according to Good Clinical Practice. The study was approved by the Research Ethics Service (RG_17-102) and was pre-registered on clinicaltrials.gov as NCT03632681.

Design
In a double-blind, placebo-controlled, crossover design, participants were randomized to receive 160 IU/1.6 mL of IN insulin (Actrapid; Novo Nordisk, Bagsvaerd, Denmark) or 160 IU/1.6 mL of placebo in a counterbalanced order. The dose was based on previous studies that reported significant effects of insulin on food intake [4, 6, 16, 23]. Placebo and insulin were identical in appearance and odour. Placebo consisted of water, 2.7 mg/ml m-cresol/mL, and 16 mg/mL glycerol (prepared by Guy’s and St Thomas’ NHS Foundation Trust’s Pharmacy Manufacturing Unit, London, UK). Placebo and insulin sprays were prepared by a pharmacist so that the study personnel and participants were unaware of group allocation. All participants took part in two sessions on two separate days at least 7 days apart. All procedures including insulin administration were overseen by medically qualified staff.

Screening session
Height and weight were measured and the participant had a medical check. Questionnaires were completed to check eligibility and characterize the sample: The Structured Clinical Interview for DSM-5, Clinical Version (SCID-CV) [24], The Beck Depression Inventory – II (BDI-II) [25], The Dutch Eating Behaviour Questionnaire (DEBQ) [26], and The Power of Food Scale (PFS) [27] (See Supplementary Table 1 for eligibility criteria).

Eating measures
Participants ate a lunch of cheese sandwiches (~588 kcal per sandwich). The portion size of which was adjusted for each participant to comprise 40% of daily energy requirements. The average portion served to each participant was 787.51 kcal (SD = ± 133.56, minimum = 565.57 kcal, maximum = 1143.56 kcal). Participants were asked to consume all of the lunch provided. Lunch was consumed prior to dosing because IN insulin has been reported to decrease consumption in women only in a postprandial state [16]. 140 min post-dosing participants were offered palatable Maryland® Chocolate Chip Cookies (along with a glass of water). Palatable cookies were chosen to allow us to examine food reward related responses. The cookies were broken up to disguise portion size (80 g) and served on a Sussex Ingestion Pattern Monitor (SIPM), which consists of a balance placed underneath the surface of a table covered by a placemat [28]. The balance was connected to a laptop that recorded the weight of the plate and alerted the participant to complete VAS ratings of hunger, fullness, and pleasantness each time 10 g of cookies was consumed (the participant was not aware of how much had been consumed). When 60 g of cookies were consumed, participants were provided with a fresh bowl of 80 g and could continue until they wished to stop. Eating rate was calculated as grams eaten/time spent eating.

Appetite / Mood measures

**Visual analogue scales (VAS).** Participants rated how they felt at that moment in relation to 14 sensations (alertness, drowsiness, happiness, hunger, fullness, desire to eat, thirst, disgust, anxiety, sadness, withdrawn, lightheaded, nausea, faint) by placing a vertical mark through a 10 cm horizontal line with left and right anchors indicating the extremes of each sensation (‘completely absent’ to ‘most I could imagine’) [28, 29].

**Positive and negative affect schedule (PANAS).** The PANAS is a 20-item scale that is a reliable and valid measure of positive and negative affect [30].

**Cognitive tasks**

**Delay discounting.** To assess ability to delay reward gratification participants completed a monetary discounting task that included nine delays. Participants saw the question ‘Which would you prefer?’, with two choices: £xx now or £xx after a delay (varying from one day to one year) and selected the preferred option. They also completed a food version in which they chose between a smaller amount of food now and a larger amount later, for example ‘Which would you prefer?’ with the options ‘one bite of chocolate now or a bar of chocolate in a month?’. Data are expressed as area under the curve [31, 32].

**Verbal paired associates (VPA).** To assess hippocampal memory participants memorized 60 associated word pairs that were presented for 2 seconds on a computer screen. Immediately after (and then again after an hour delay) they received a cue word and responded aloud with the target word [33].

**N-Back.** To assess working memory blue circles were presented on a white 3x3 grid for 500 ms. Participants indicated if the circle was in the same position or a different position as it was two (2-back) and three trials back (3-back). Accuracy and reaction times (RT) for correct responses by stimuli (2 and 3-back) were recorded [34].

**P1vital® oxford emotional test battery**

Emotional categorisation task (ECAT): (see [35]; [www.p1vital.com]). Sixty positive and negative adjectives were presented for 500 ms. Participants indicated whether they would like or dislike to be described as such. RT by valence and accuracy (selection of positive adjectives for self-reference/rejecting negative adjectives for self-reference) were measured.
analysed using SPM12 standard procedures [37]. For each subject a catheter was inserted into an antecubital vein of the forearm of the

Four blood samples (4 mL) were collected via an intravenous catheter inserted as a safety precaution. Blood samples were kept on ice or stored at −80 °C until centrifuged at 1500 × g for 15 min. At the end of the test day, capillary blood glucose was measured to ensure euglycaemia prior to the participant’s departure.

Procedure
Participants completed baseline VAS and PANAS, had a medical check and blood draw. They then consumed lunch and afterwards completed a set of the VAS/PANAS and self-administered the IN insulin by inhaling 0.1 mL of insulin or placebo in a single puff. There were eight puffs per nostril giving a total of 1.6 mL and 30-second intervals between puffs. 5 min post-IN insulin administration, there was a blood draw and VAS/PANAS completed.

Participants then underwent the fMRI scan for 1.5 h during which they completed an inhibition task (results not reported here) and the picture rating task. Participants then completed the DD task, VAS/PANAS and had another blood draw, after which they consumed chocolate cookies. The final blood draw was taken and another set of VAS/PANAS completed. The participants then completed the immediate recall phase of the VPA, the N-back and ETB followed by VAS/PANAS. The delayed recall phase of the VPA was then completed. Next, the participants had 5 min to recall the images that were presented in the scanner and then completed a final set of VAS/PANAS. See Fig. 1.

Emotional recall task (ERE): Participants were given four minutes to recall as many words from the ECAT task as they could within 4-mins. Accuracy and commission errors by valence were analyzed.

Emotional recognition memory task (EMEM): Participants were presented with 60 personality descriptor words, along with 60 matching novel distractor words and indicated whether the word had been presented during the ECAT. Percentage accuracy, RT for correct responses and commission errors were analyzed by valence.

fMRI picture rating task
Participants viewed food and non-food pictures (36 from each category and visually matched) [36]. The food pictures varied in fat and sugar content (high fat, high sugar; high fat low sugar; low fat high sugar and low fat, low sugar). Items were rated on appeal using a scale from 1 (not at all) to 5 (very much). Each picture was presented for 1500 ms, followed by a fixation cross (500–1500 ms).

At the end of the test day, participants were asked to recall as many of the pictures as possible and to record these responses on paper. Accuracy (percentage correct recalled) by category was analyzed.

Acquisition, processing and analysis of fMRI data
Data were collected using a 3-Tesla Phillips Achieva MRI scanner with a 32-channel head coil at the Birmingham University Imaging Centre. Functional images during the picture task (3 × 185 volumes) were acquired with a single-shot echo-planar imaging (EPI) sequence: repetition time (TR = 2400 ms), adjusted flip angle (77°), echo time (TE = 30 ms), and 43 transverse slices (voxel size = 3 × 3 × 2 mm³). A gradient echo field map was also acquired (echo time (short) = 9.2 ms, echo time (long = 11.5 ms), flip angle = 90°).

The T1-weighted anatomical scan was acquired with a TR/TE of 7.4/3.5 ms, a flip angle of 7°, FOV of 256 × 256 × 176 mm, 176 sagittal slices, and a voxel size of 1×1×1 mm³. Data were analysed using SPM12 standard procedures [37]. For each subject a model contained 4 regressors: four food stimulus categories and four matched non-food stimulus categories resulting in two contrast images: food versus matched non-food pictures. Six motion parameters were included. Contrast images from subject level were entered into a second level within-subjects ANOVA (insulin versus placebo).

Blood insulin and glucose
Four blood samples (4 mL) were collected via an intravenous catheter inserted into an antecubital vein of the forearm of the participant’s choice at baseline, 5, 135 and 155 min post-IN insulin administration for the determination of haemoglobin (HbA1C; mmol/mol) on test day one and insulin and glucose on both test days. A small sample of blood collected from the intravenous catheter was tested at each timepoint to check for hypoglycaemia as a safety precaution. Blood samples were kept on ice or stored as a safety precaution. Blood samples were kept on ice or stored...
insulin on rated pleasantness at the end of the session ($F(1, 47) = 0.99, \eta_p^2 = 0.34, p = 0.34$). There were no significant main effects of IN insulin on initial cookie liking for women with obesity ($F(1, 15) = 2.87, p = 0.09$) and follow-up tests revealed reduced intake of cookies for women with obesity ($t(16) = 2.12, p = 0.08$) and no effect for lean women ($t(16) = 0.55, p = 0.59, d = 0.07$). There was a main effect of IN insulin on initial ratings of cookie palatability ($F(1, 47) = 4.83, p = 0.03, \eta_p^2 = 0.09$) and follow-up tests showed that IN insulin reduced initial cookie liking for women with obesity ($t(15) = -2.87, p = 0.01, d = 0.42$) but not for lean women ($t(34) = -0.34, p = 0.74, d = 0.04$). There was no main effect of IN insulin on rated pleasantness at the end of the session ($F(1, 47) = 0.01, p = 0.99, \eta_p^2 < 0.01$). There was no effect of IN insulin on eating rate ($F(1, 47) = 0.02, p = 0.89, \eta_p^2 < 0.01$) (Fig. 2).

**Appetite and Mood**

IN insulin reduced appetite ($F(1, 50) = 5.66, p = 0.02, \eta_p^2 = 0.10$) and this effect was more pronounced for women with obesity ($t(16) = -2.11, p = 0.051, d = 0.60$) than for lean women ($t(34) = -0.74, p = 0.47, d = 0.11$). There were no significant main effects of IN insulin on arousal ($F(1, 50) = 2.16, p = 0.15, \eta_p^2 = 0.04$), negative effects ($F(1, 50) = 1.39, p = 0.24, \eta_p^2 = 0.03$), physical effects ($F(1, 50) = 0.06, p = 0.81, \eta_p^2 < 0.01$), and thirst ($F(1, 50) = 0.01, p = 0.98, \eta_p^2 < 0.01$).

There was no significant main effect of IN insulin on PANAS ratings ($F(1, 47) = 3.78, p = 0.06, \eta_p^2 = 0.07$), but the interaction between IN insulin and BMI was significant ($F(1, 47) = 5.47, p = 0.02, \eta_p^2 = 0.10$) which was explained by a significant increase of positive affect (PA) ratings for women with obesity ($t(16) = 2.86, p = 0.01, d = 0.42$) (Fig. 3).

**Cognitive tasks**

The only effect of IN insulin was improved accuracy for selection of self-referent positive adjectives and rejection of negative adjectives and slower RT on the n-back task for women with obesity. See below for statistical results and Supplementary Table 3 for descriptive statistics.

**VPA.** The effect of IN insulin condition on recall accuracy was not significant ($F(1, 50) = 0.01, p = 0.93, \eta_p^2 < 0.01$).

**ETB – ECAT.** IN insulin improved accuracy for selection of positive adjectives for self-reference and rejecting negative adjectives for self-reference ($F(1, 49) = 6.76, p = 0.01, \eta_p^2 = 0.12$). Follow-up tests revealed no significant differences of IN insulin on ECAT accuracy for lean women ($t(32) = 1.87, p = 0.07, d = 0.22$) nor women with obesity ($t(16) = 1.72, p = 0.10, d = 0.49$). The effect of IN insulin on RT ($F(1, 48) = 1.64, p = 0.21, \eta_p^2 = 0.03$) was not significant.

**RESULTS**

**Demographics**

Women with obesity had a higher BMI and self-reported more restrained and emotional eating in line with previous research (e.g., [38, 39]). See Supplementary Table 2 for participation demographics.

**Cookie intake**

There was a main effect of IN insulin on cookie intake ($F(1, 50) = 4.59, p = 0.04, \eta_p^2 = 0.08$) and follow-up tests revealed reduced intake of cookies for women with obesity ($t(16) = -2.12, p = 0.05, d = 0.46$) and no effect for lean women ($t(34) = -0.55, p = 0.59, d = 0.07$). There was a main effect of IN insulin on initial ratings of cookie pleasantness ($F(1, 47) = 4.83, p = 0.03, \eta_p^2 = 0.09$) and follow-up tests showed that IN insulin reduced initial cookie liking for women with obesity ($t(15) = -2.87, p = 0.01, d = 0.42$) but not for lean women ($t(32) = -0.34, p = 0.74, d = 0.04$). There was no main effect of IN insulin on rated pleasantness at the end of the session ($F(1, 47) = 0.01, p = 0.99, \eta_p^2 < 0.01$). There was no effect of IN insulin on eating rate ($F(1, 47) = 0.02, p = 0.89, \eta_p^2 < 0.01$) (Fig. 2).

**Appetite and Mood**

IN insulin reduced appetite ($F(1, 50) = 5.66, p = 0.02, \eta_p^2 = 0.10$) and this effect was more pronounced for women with obesity ($t(16) = -2.11, p = 0.051, d = 0.60$) than for lean women ($t(34) = -0.74, p = 0.47, d = 0.11$). There were no significant main effects of IN insulin on arousal ($F(1, 50) = 2.16, p = 0.15, \eta_p^2 = 0.04$), negative effects ($F(1, 50) = 1.39, p = 0.24, \eta_p^2 = 0.03$), physical effects ($F(1, 50) = 0.06, p = 0.81, \eta_p^2 < 0.01$), and thirst ($F(1, 50) = 0.01, p = 0.98, \eta_p^2 < 0.01$).

There was no significant main effect of IN insulin on PANAS ratings ($F(1, 47) = 3.78, p = 0.06, \eta_p^2 = 0.07$), but the interaction between IN insulin and BMI was significant ($F(1, 47) = 5.47, p = 0.02, \eta_p^2 = 0.10$) which was explained by a significant increase of positive affect (PA) ratings for women with obesity ($t(16) = 2.86, p = 0.01, d = 0.42$) (Fig. 3).

**Cognitive tasks**

The only effect of IN insulin was improved accuracy for selection of self-referent positive adjectives and rejection of negative adjectives and slower RT on the n-back task for women with obesity. See below for statistical results and Supplementary Table 3 for descriptive statistics.

**VPA.** The effect of IN insulin condition on recall accuracy was not significant ($F(1, 50) = 0.01, p = 0.93, \eta_p^2 < 0.01$).

**ETB – ECAT.** IN insulin improved accuracy for selection of positive adjectives for self-reference and rejecting negative adjectives for self-reference ($F(1, 49) = 6.76, p = 0.01, \eta_p^2 = 0.12$). Follow-up tests revealed no significant differences of IN insulin on ECAT accuracy for lean women ($t(32) = 1.87, p = 0.07, d = 0.22$) nor women with obesity ($t(16) = 1.72, p = 0.10, d = 0.49$). The effect of IN insulin on RT ($F(1, 48) = 1.64, p = 0.21, \eta_p^2 = 0.03$) was not significant.
The effect of IN insulin on recall (PRT recall) was significant. The interaction between IN insulin and BMI for accuracy was revealed no significance at 0.05 level. There was no effect of IN insulin on accuracy (F(1,50) = 0.3) or RT (F(1,49) = 0.01, d = 0.56). PRT recall. The effect of IN insulin on recall (F(1,49) = 0.01, p = 0.94, \eta_p^2 < 0.01) was not significant.

**Picture rating task**

**Pleasantness ratings.** There was no significant effect of IN insulin on pleasantness ratings of food stimuli (F(1,43) = 1.32, p = 0.26, \eta_p^2 = 0.3).

**fMRI.** Statistically significantly greater (whole-brain FWE-corrected) blood-oxygen-level-dependent (BOLD) responses to food compared to non-food images (independent of condition) were observed in the left precuneus (n voxels = 427, xyz = [−6,51,18], Z = 5.46, p < 0.001), left superior frontal gyrus (n voxels = 611, xyz = [−6,3,−3], Z = 4.78, p < 0.001), left thalamus (n voxels = 99, xyz = [−3,−16,6], Z = 4.56, p = 0.031), left orbitofrontal cortex (n voxels = 121, xyz = [−30,12,9], Z = 4.52, p = 0.016), and left inferior temporal cortex (n voxels = 99, xyz = [−30,66,45], Z = 4.16, p = 0.046). All ps FWE-corrected.

Under a whole-brain FWE-corrected significance threshold, the BOLD response in the left insula [−45,0,6] when viewing food versus non-food pictures was significantly greater in the insulin condition compared to placebo in both BMI groups (n voxels = 107, Z = 4.47, p = 0.038) (see Fig. 4). No regions showed an attenuation of activity after insulin compared to placebo. There was no interaction between food category and treatment.

**Blood insulin and glucose**

Pre-dose blood glucose did not differ according to BMI (F(1,49) = 0.97, p = 0.33, \eta_p^2 = 0.02) or test day (F(1,49) = 0.32, p = 0.58, \eta_p^2 = 0.01) (Supplementary Table 4). IN insulin had no effect on blood glucose (F(1,48) = 0.10, p = 0.75, \eta_p^2 < 0.01) (Supplementary Table 4).

Women with obesity had higher baseline blood insulin than lean women (F(1,44) = 7.03, p = 0.01, \eta_p^2 = 0.14). Women with
obesity had higher post-dose blood insulin concentrations than lean women \( F(1,44) = 13.04, p < 0.01, \eta^2_p = 0.23 \). There was a significant increase in blood insulin after IN insulin at 5 min post-dose \( t(45) = 3.24, p < 0.01, d = 0.36 \) (see Fig. 5).

**DISCUSSION**

A post-prandial acute dose of IN insulin reduced cookie intake, appetite and the reward value of cookies in women. These effects were stronger for women with obesity compared with lean women. IN insulin improved mood in women with obesity. In both BMI groups, IN insulin increased the BOLD fMRI signal in the insula when viewing food (versus non-food) pictures. IN insulin did not improve cognitive function. Taken together these results suggest that IN insulin may reduce food intake by influencing food reward processes and that women with obesity may be more sensitive to these effects than lean women.

Given previous reports of blunted effects of IN insulin in individuals with obesity [13, 15, 18, 22, 40] presenting with peripheral insulin resistance [41] we hypothesized that participants with obesity could be less responsive to effects of IN insulin than lean women. In our sample, women with obesity had higher baseline blood levels of insulin compared with lean participants but did not differ in blood glucose levels and had normal HbA1c levels. This suggests that elevated insulin release may have compensated for reduced insulin sensitivity. It might be argued that IN insulin had effects in the women with obesity in our study because they retained sensitivity to intracerebral (rather than

---

**Fig. 4** fMRI. Top panel: Significant cluster (FWE-corrected \( p < 0.05 \)) in the left insula for contrast Insulin > Placebo. Figure thresholded at initial uncorrected detection threshold \( p < 0.001 \). Bottom panel: Parameter estimates from left insula cluster \([-45,0,6]\). Asterisks denote significant difference between placebo (light grey fill) and insulin (dark grey fill) for both lean participants and participants with obesity at 0.05 level. Squares depict the mean.
Insulin. In aged mice showing an attenuated effect on cortical activity of subcutaneously administered insulin, intracerebroventricular insulin delivery yielded a response similar to that seen in young animals [42]. Accordingly, the compromised brain effect of endogenous or peripherally administered insulin in obesity might stem primarily from attenuated insulin transport to the brain as a result of hyperinsulinaemia [43, 44], which can be overcome by directly targeting the brain with IN insulin [45]. The decrease in initial pleasantness of the palatable cookies after IN insulin suggests that the decrease in intake may be mediated by reduced food reward. Since the participants were in a post-prandial state when insulin was administered and cookies were offered, it is conceivable that IN insulin enhanced postprandial signals that reduce food reward when satiated. This is important because reductions in reward-related responding that are specific to the satiated state are likely to be effective in helping individuals to curb their appetite but are unlikely to reduce hedonic responding in general. However, in order to further understand the scope of the effect, future studies should examine the effects of IN insulin on intake of a range of foods varying in palatability and macronutrient content.

Further support for a specific effect of IN insulin on post-prandial signals comes from the fMRI data. Greater BOLD fMRI responses were elicited by viewing food compared to non-food images across several brain regions and in line with effects on eating behaviour, we observed an increased BOLD signal in response to food images in mid insula following IN insulin. This is consistent with evidence for a high density of insulin receptors in the insula [46] and that insulin facilitates neuronal firing in the insular cortex of mice [47] and increases neuronal excitability via a reduction in calcium dependent afterhyperpolarization [48]. The insula is hypothesized to integrate interoceptive and exteroceptive appetite and food reward signals [49, 50]. Hence, IN insulin-induced activation of the insula might enhance postprandial signals that nutrients have been consumed, which in turn decreases the attractiveness of food.

Increased insula activation by IN insulin was observed in both BMI groups, but effects on appetite and food intake were observed only in women with obesity. Our task may have identified effects of IN insulin on processing of interoceptive signals in both lean women and women with obesity, but whether these actions were translated into reduced food intake could have depended upon downstream neural processes during food consumption that varied according to BMI status. One possibility is that women with obesity may have impaired interoception [51] and thereby benefit from enhanced interoceptive signals more than lean women.

Contrary to the results of Hallschmid et al. [16], we did not find a robust effect of IN insulin on cookie intake in lean women. Our study offered only one cookie type, while participants in the Hallschmid et al. [16] study were offered three varieties and IN insulin affected intake of the most palatable cookies. Variety stimulates intake [52] and so effects of IN insulin on cookie intake in lean women in the previous study [16] may have been related to the range of palatable options. There was substantial variability in the cookie intake of lean women in the placebo condition suggesting that not all found the cookies palatable in the present study. Therefore, it may be that because effects of IN insulin on intake are most pronounced for palatable foods we could have seen an effect if more palatable options had been provided.

Unlike previous studies [13–15] we saw no effects of IN insulin in brain regions associated with food reward or in the hypothalamus. However, most previous studies examined effects of IN insulin on resting state activity and in fasted participants [14, 15, 53], whereas we examined task related (picture rating) activity in satiated participants. This suggests that the effect of IN insulin on neural responses may vary depending upon nutritional state. Future investigations should examine how the neural responses to food cues in lean individuals and individuals with obesity are altered by IN insulin depending on their fed versus fasted state.

Intranasal insulin increased working memory RT of women with obesity but had no other effect on cognitive measures for either BMI group. This suggests that cognitive processes do not underlie the effects of IN insulin on food intake and appetite although the cognitive tasks used may have been insufficiently sensitive to detect effects of IN insulin on memory. Previous studies used a spatial memory task [4], which may be more sensitive to hippocampal effects of IN insulin.

We observed enhancement of mood after IN insulin for women with obesity. This is consistent with reports of IN insulin-induced mood improvement in men with obesity [9, 54]. The ability of IN insulin to decrease appetite and food intake in women with obesity combined with its mood enhancing effects are very promising in terms of therapeutic use of the hormone, especially given the co-morbidity of obesity, diabetes and mood disorders [55, 56]. Moreover, while there was an increase in blood insulin levels 5 mins after administration, suggesting some spillover of IN insulin into circulation, blood glucose levels were unchanged throughout the test day, highlighting the safety of the intervention.

This study has some limitations. The uneven and smaller sample size for participants with obesity may have masked statistical effects, although the large effect sizes suggest that they are robust.

In summary, we provide evidence that IN insulin reduces appetite and food intake and increases positive mood in women with obesity. These results show promise for the therapeutic use of IN insulin as a weight management option for women with obesity, particularly those with co-morbid mood disorders and further investigation of the longer-term effects of the hormone on weight in women with obesity is warranted.

**DATA AVAILABILITY**

Data for this study will be made available in a public archive following publication of this study. In the interim, data are available upon request.
REFERENCES

1. Woods SC, Lotter EC, McKay LD, Porte D. Chronic intracerebroventricular infusion of insulin reduces food intake and body weight of baboons. Nature. 1979;282:503–5. https://doi.org/10.1038/282503a0

2. Porte DJ, Baskin DG, Schwartz MW. Insulin signaling in the central nervous system: a critical role in metabolic homeostasis and disease from C. elegans to humans. Diabetes. 2005;54:1264–76. https://doi.org/10.2337/diabetes.54.5.1264

3. Born J, Lange T, Kern W, McGregor GP, Bickel U, Fehm HL. Sniffing neuroresponses: a transcranial approach to the human brain. Nat Neurosci. 2002;5:314–6. https://doi.org/10.1038/nn849

4. Benedict C, Kern W, Schultz B, Born J, Hallschmid M. Differential sensitivity of men and women to anorexigenic and memory-improving effects of intranasal insulin. J Clin Endocrinol Metab. 2008;93:1339–44. https://doi.org/10.1210/jc.2007-1813

5. Jauch-Chara K, Friedrich A, Rezmer M, Melchert UH, Scholander-Engler HG, Hallschmid M, et al. Intranasal insulin before nociception induces satiety and reduces food intake in humans. Diabetes. 2012;61:2261–5. https://doi.org/10.2337/db12-0025

6. Santiago JCP, Hallschmid M. Central nervous insulin administration before nocurnal sleep decreases breakfast intake in healthy young and elderly subjects. Front Neurosci. 2017;11:54. https://doi.org/10.3389/fnins.2017.00054

7. Hallschmid M, Benedict C, Schultz B, Fehm HL, Born J, Kern W. Intranasal insulin reduces body fat in men but not in women. Diabetes. 2004;53:3024–9. https://doi.org/10.2337/diabetes.53.11.3024

8. Hallschmid M, Benedict C, Schultz B, Born J, Kern W. Obese men respond to cognitive but not to catabolic brain insulin signaling. Int J Obes. 2008;32:275–82. https://doi.org/10.1038/ijo.2008.37322

9. Ritze Y, Kern W, Ebner E-M, Jahn S, Benedict C, Hallschmid M. Metabolic and cognitive but not to catabolic brain insulin signaling. Int J Obes. 2008;32:275–82. https://doi.org/10.1038/ijo.2008.37322

10. Ritze Y, Kern W, Ebner E-M, Jahn S, Benedict C, Hallschmid M. Metabolic and Cognitive But not to Catabolic Brain Insulin Signaling. Int J Obes. 2008;32:275–82. https://doi.org/10.1038/ijo.2008.37322

11. Rodriguez-Raecke R, Sommer M, Brünner YM, Müschener F, Sibgen R. Virtual grocery shopping and cookie consumption following intranasal insulin or placebo application. Exp Clin Psychopharmacol. 2020;28:495–500. https://doi.org/10.1037/pha0000330

12. Opstal AM, Akintola AA, Elst MV, Westendorp RG, Pijl H, Heemst DV, et al. Effects of the SHT2 receptor agonist meta-chlorophenylpiperazine (mCPP) reduces palatable food consumption and BOLD fMRI responses to food images in healthy female volunteers. Psychopharmacology (Berl). 2018;235:257–67. https://doi.org/10.1007/s00213-017-4764-9

13. Thomas JM, Dourish CT, Tomlinson JW, Hassan-Smith Z, Higgs S. The S-HT2C receptor agonist meta-chlorophenylpiperazine on appetite, food intake and emotional processing in healthy volunteers. Psychopharmacology (Berl). 2014;231:2449–59. https://doi.org/10.1007/s00213-013-3409-x

14. Crawford JR, Henry JD. The Positive and Negative Affect Schedule (PANAS): Construct validity, measurement properties and normative data in a large non-clinical sample. Br J Clin Psychol. 2004;43(3 Pt 2):245–65. https://doi.org/10.1348/0144665031752935

15. Moreira D, Barbosa F. Delay Discounting in Impulsive Behavior: A Systematic Review. Eur Psychol. 2019;24:312–21. https://doi.org/10.1027/1016-9040/a000340

16. Davis C, Patte K, Curtis C, Reid C. Immediate pleasures and future consequences. A neuropsychological study of binge eating and obesity. Appetite. 2010;54:208–13. https://doi.org/10.1016/j.appet.2009.11.002

17. Clark IA, Kim M, Maguire EA. Verbal paired associates and the hippocampus: The role of scenes. J Cogn Neurosci. 2018;30:1821–45. https://doi.org/10.1162/jocn_a_01315

18. Kirchner WK. Age differences in short-term retention of rapidly changing information. J Exp Psychol. 1958;55:352–8. https://doi.org/10.1037/h0043688

19. Thomas JM, Higgs S, Dourish CT. Test-retest reliability and effects of repeated testing on stability of performance on an Emotional Test Battery. J Clin Exp Neuropsychol. 2016;38:416–33. https://doi.org/10.1080/13803395.2015.1121969

20. Chechelac M, Rotshtein P, Klamer S, Porubskas K, Higgs S, Booth D, et al. Diabetes dietary management alters responses to food pictures in brain regions associated with motivation and emotion: a functional magnetic resonance imaging study. Diabetologia. 2009;52:524–33. https://doi.org/10.1007/s00125-009-1253-z

21. Friston KJ, Jezzard P, Turner R. Analysis of functional MRI time-series. Hum Brain Mapp. 1994;1:53–71. https://doi.org/10.1002/hbm.460010207

22. Brunault P, Rabemampianina I, Apfeldorfer G, Ballon N, Couet C, Révilleur C, et al. The Dutch Eating Behavior Questionnaire: Further psychometric validation and clinical implications of the French version in normal weight and obese persons. Presse Med. 2015;44(3):636–72. https://doi.org/10.1016/j.pmed.2015.03.028

23. Castellanos EH, Charlboneau E, Dietrich MS, Park S, Bradley BF, Mogk K, et al. Obese adolescent girls have increased reward bias for food cue images: evidence for altered reward system function. Int J Obes (Lond). 2009;33:163–73. https://doi.org/10.1038/ijob.2009.138

24. Guthoff M, Stirling KT, Tschritter O, Richter M, Prager C, Scharf R, et al. The insulin-mediated modulation of visually evoked magnetic fields is reduced in obese subjects. PLoS One. 2011;6:e19482. https://doi.org/10.1371/journal.pone.0019482

25. Hallermeier C, Heni M, Hallschmid M, Fritsche A, Häring HU. Brain insulin resistance at the crossroads of metabolic and cognitive disorders in humans. Physiol Rev. 2016;96:1169–209. https://doi.org/10.1152/physrev.00032.2015

26. Sartorius T, Peter A, Heni M, Maetzler W, Fritsche A, Häring HU, et al. The brain response to peripheral insulin declines with age: a contribution of the blood-brain barrier? PLoS One. 2015;10:e0126804. https://doi.org/10.1371/journal.pone.0126804

27. Kaiyala KJ, Priggeon RL, Kahn SE, Schwartz MW. Obesity induced by a high-fat diet is associated with reduced brain insulin transport in dogs. Diabetes. 2000;49:1525–33. https://doi.org/10.2337/diabetes.49.9.1525

28. Urayama A, Banks WA. Starvation and triglycerides reverse the obesity-induced impairment of insulin transport at the blood-brain barrier. Endocrinology. 2005;146:3592–7. https://doi.org/10.1210/eb-08-16-3592

29. Frazier NH, Ghoweri AO, Anderson KL, Lin RL, Porter NM, Thibault O. Broadening the definition of brain insulin resistance in aging and Alzheimer’s disease. Exp Neurol. 2019;313:79–87. https://doi.org/10.1016/j.expneurol.2018.12.007

30. Schulingkamp RJ, Pagano TC, Hing D, Raffa RB. Insulin receptors and insulin action in the brain: review and clinical implications. Neurosci Biobehav Rev. 2000;24:855–72. https://doi.org/10.1016/S0306-4565(00)00043-0
ACKNOWLEDGEMENTS

Funding for this work was provided by BBSRC Grant UK awarded to SH grant number: BB/N008847/1 and supported by the NIHR funded Birmingham Clinical Research Facility. The BBSRC/NIHR had no further role in study design; in the collection, analysis and interpretation of data; in the writing of the report; and in the decision to submit the paper for publication. The behavioural results of this study have been previously presented in poster format at the American College of Neuropsychopharmacology conference in 2019 and the European College of Neuropsychopharmacology conference in 2020. We would like to thank Nina Avitable, Jennie Gavin, Hafwen Thornhill, Saleema Islam, Dr Ross Wilson, and Nina Salman for their invaluable assistance with data collection.

AUTHOR CONTRIBUTIONS

Authors MSS, JMT, ML, MH, PR CTD, and SH are responsible for the design of this research. Authors ES, MSS, and EM collected the data. Authors KPY, ESapey, KM, and AAT provided medical cover and oversaw patient safety, drug prescription, and drug administration. Authors ES and EM analyzed the data. Authors PR, CTD, and SH provided supervision for ES and EM. All authors have contributed to writing and reviewing the manuscript. SH is the guarantor of the work and, as such, had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

COMPETING INTERESTS

AAT reports grants from Novo Nordisk, personal fees from Novo Nordisk, non-financial support from Novo Nordisk, personal fees from Eli Lilly, non-financial support from Eli Lilly, non-financial support from Janssen, personal fees from AstraZeneca, non-financial support from AstraZeneca, non-financial support from Impeto medical, non-financial support from Resmed, non-financial support from Aptiva, personal fees from Boehringer Ingelheim, non-financial support from Boehringer Ingelheim, personal fees from Bristol Myers Squibb, non-financial support from Bristol Myers Squibb, personal fees from NAPP, non-financial support from NAPP, personal fees from Merck Sharp & Dohme, non-financial support from Merck Sharp & Dohme, personal fees from Nestle, personal fees from Gilead, grants from Sanofi, and personal fees from Sanofi outside the submitted work. AAT is currently an employee of Novo Nordisk. This work was performed before AAT became a Novo Nordisk employee. Novo Nordisk had no role in this study. CTD is a Director and Co-Owner of P1vital Limited and a Director and Co-Owner of P1vital Products Limited. All other authors declare no competing interests.

ADDITIONAL INFORMATION

Supplementary information
Supplementary information is available at https://doi.org/10.1038/s41366-022-01115-1.

Correspondence
Correspondence and requests for materials should be addressed to Suzanne Higgs.

Reprints and permission information
Reprints and permission information is available at http://www.nature.com/reprints.

Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access
This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2022

International Journal of Obesity (2022) 46:1319 – 1327